Microbiome Connect: Europe 2023

Microbiome Connect: Where innovation meets industry

Microbiome Connect: Europe Returns July 2023

REGISTER YOUR INTEREST
AMSTERDAM, NETHERLANDS
July 2023

How To Get Involved

PARTNER WITH US

It's never too early to get involved! Based on your objectives, we can create bespoke packages designed specifically for you.

From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Discuss your objectives with Simon Pickle, Commercial Partnerships Lead; [email protected]

REGISTER AS A DELEGATE

As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers need the opportunity to benchmark their drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.

Step into interactive discussions and engaging presentations on the hottest challenges facing the Microbiome industry today. Book here today at our pre-launch rate to benefit from the lowest available prices.

OR REGISTER YOUR INTEREST IN THE 2023 AGENDA HERE.

Previous Speakers

 

Jean-Luc Marsat

CEO
Everimmune

Jean-Luc Marsat

CEO
Everimmune

Jean-Luc Marsat

CEO
Everimmune
 

Anders Kronström

COO
Infant Bacterial Therapeutics

Anders Kronström

COO
Infant Bacterial Therapeutics

Anders Kronström

COO
Infant Bacterial Therapeutics
 

Staffan Stromberg

CEO
Infant Bacterial Therapeutics

Staffan Stromberg

CEO
Infant Bacterial Therapeutics

Staffan Stromberg

CEO
Infant Bacterial Therapeutics
 

Dr Jenny Bailey

Co-Founder and CEO
Ferryx

Dr Jenny Bailey

Co-Founder and CEO
Ferryx

Dr Jenny Bailey

Co-Founder and CEO
Ferryx
 

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology.

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology. He currently acts as head of the preclinical research of EverImmune.

 

Luc Sterkman

CEO
Caelus Health B.V.

Luc Sterkman

CEO
Caelus Health B.V.

Luc Sterkman

CEO
Caelus Health B.V.
 

Nigel Titford

CEO
BioGaia Pharma

Nigel Titford

CEO
BioGaia Pharma

Nigel Titford

CEO
BioGaia Pharma
 

Ghaith Bakdash PhD

Director
Microbiotica

Ghaith Bakdash is an immunologist with broad experience ranging from immune oncology to autoimmune disease and mucosal immunology. Following his PhD at the University of Amsterdam, his interest in translational research led him to a post-doc position at Radboud University Medical Cetner in Nijmegen, the Netherlands, where he contributed to the development of dendritic cell-based cancer vaccines.

Ghaith Bakdash PhD

Director
Microbiotica

Ghaith Bakdash PhD

Director
Microbiotica

Ghaith Bakdash is an immunologist with broad experience ranging from immune oncology to autoimmune disease and mucosal immunology. Following his PhD at the University of Amsterdam, his interest in translational research led him to a post-doc position at Radboud University Medical Cetner in Nijmegen, the Netherlands, where he contributed to the development of dendritic cell-based cancer vaccines. Later, he joined GSK as an investigator in the Respiratory Therapy Area, where he was participating in the development of new modalities to induce immune tolerance in the context of allergy and asthma. Currently, he is an Associate Director at Microbiotica, where he is leading the efforts of the Cell Biology team in live bacterial therapies development by elucidating the interactions between these therapeutic bacteria and host cells in the context of cancer and ulcerative colitis.

 

Sheri Meshner

CSO
Biomica

Sheri Meshner

CSO
Biomica

Sheri Meshner

CSO
Biomica
 

Sophie Declomesnil

Process Development Director
4D Pharma

Sophie Declomesnil

Process Development Director
4D Pharma

Sophie Declomesnil

Process Development Director
4D Pharma
 

Chrysi Sergaki

Principal Investigator / Microbiome Group Leader
NIBSC/MHRA

Dr Chrysi Sergaki is the interim Head of Microbiome section at the National Institute for Biological Standards and Control (NIBSC), working on microbial interactions and how to utilise them for the benefit of human health.

Chrysi Sergaki

Principal Investigator / Microbiome Group Leader
NIBSC/MHRA

Chrysi Sergaki

Principal Investigator / Microbiome Group Leader
NIBSC/MHRA

Dr Chrysi Sergaki is the interim Head of Microbiome section at the National Institute for Biological Standards and Control (NIBSC), working on microbial interactions and how to utilise them for the benefit of human health.

At NIBSC, Chrysi is leading the microbiome standardisation program, with 18 World Health Organization (WHO) endorsed project to develop International Reference Reagents for the microbiome field as well as research projects investigating the role of the microbiome in gut health and disease. Prior to this, Chrysi has been working at NIBSC as scientist for two years leading research projects as well as the development of reference reagents for the DNA extraction of microbiome samples and will be evaluated as candidates for the first World Health Organization Whole Cell Reference Reagents for the microbiome.

Before joining the NIBSC in 2019, Chrysi completed her PhD at the University of Warwick, UK, researching microbial interactions in fungi and bacteria and their impact on the host by combining laboratory and bioinformatics approaches.

 

Henrik Bjørn Nielsen

CSO
Clinical Microbiomics

Henrik Bjørn Nielsen

CSO
Clinical Microbiomics

Henrik Bjørn Nielsen

CSO
Clinical Microbiomics
 

Eric Van der Helm

VP Scientific Affairs
SNIPR Bio

Eric Van der Helm

VP Scientific Affairs
SNIPR Bio

Eric Van der Helm

VP Scientific Affairs
SNIPR Bio
 

Fabio Grassi

CEO
MVBiotherapeutics

Fabio Grassi

CEO
MVBiotherapeutics

Fabio Grassi

CEO
MVBiotherapeutics
 

Jean de Gunzburg

CSO
Davoltera

Talk to me about… your research

Jean de Gunzburg

CSO
Davoltera

Jean de Gunzburg

CSO
Davoltera

Talk to me about… your research

I am the chief scientific officer at Da Volterra, a French biotechnology company, headquartered in Paris, France. Da Volterra is committed to the discovery and development of innovative approaches to prevent the deleterious consequences of antibiotic treatments on the intestinal microbiota, including the emer­gence and dissemination of antimicrobial resistance, as well as the occurrence of infections by opportunistic pathogens such as Clostridium difficile. Prior to that, I led an academic career as a cell biologist focusing on signal transduction and oncogenesis, ultimately leading a research laboratory at the Institut Curie in Paris.

 

Talk to me about…something people may not know about you

I was born in Canada, lived for most of my life in France, and am now based in the London. I am an avid off-piste skier, in the French and Swiss Alps. I particularly enjoy the slow hiking/skinning up the mountains which gives me time to appreciate the fabulous scenery, and to think in depth about new and arising matters, in particular in relation to my research.

 

Niall Hyland

Senior Lecturer, Department of Physiology
University College Cork

Niall Hyland

Senior Lecturer, Department of Physiology
University College Cork

Niall Hyland

Senior Lecturer, Department of Physiology
University College Cork
 

Rikke Nielson

CEO
BEO Therapeutics

Rikke Nielson

CEO
BEO Therapeutics

Rikke Nielson

CEO
BEO Therapeutics
 

Robert JM Brummer MD PhD

Pro-Vice-Chancellor, Food & Health
Orebro University

Robert JM Brummer MD PhD

Pro-Vice-Chancellor, Food & Health
Orebro University

Robert JM Brummer MD PhD

Pro-Vice-Chancellor, Food & Health
Orebro University
 

Sam Possemiers

CEO
MRMHealth

Sam Possemiers

CEO
MRMHealth

Sam Possemiers

CEO
MRMHealth
 

Vivek Lal

CEO
Alveolus Bio

Vivek Lal

CEO
Alveolus Bio

Vivek Lal

CEO
Alveolus Bio
 

Morten Isaksen

Chief Innovation Officer & Founder
Bio-Me AS

Morten Isaksen

Chief Innovation Officer & Founder
Bio-Me AS

Morten Isaksen

Chief Innovation Officer & Founder
Bio-Me AS
 

Bharat Dixit

VP, Biopharmaceutical Development & Manufacturing
Artugen Therapeutics

Bharat Dixit

VP, Biopharmaceutical Development & Manufacturing
Artugen Therapeutics

Bharat Dixit

VP, Biopharmaceutical Development & Manufacturing
Artugen Therapeutics
 

Frederic Elustondo

Senior Director of Operations
YSOPIA

Frederic Elustondo

Senior Director of Operations
YSOPIA

Frederic Elustondo

Senior Director of Operations
YSOPIA
 

Gabriel Leventhal

Head of R&D
PharmaBiome

Gabriel Leventhal

Head of R&D
PharmaBiome

Gabriel Leventhal

Head of R&D
PharmaBiome
 

Anna Kattel Ph.D

Researcher
Tallinn University of Technology

Anna is a third-year industrial PhD student at Tallinn University of Technology (TalTech). She is doing her research at the Center of Food and Fermentation Technologies (TFTAK).

Anna Kattel Ph.D

Researcher
Tallinn University of Technology

Anna Kattel Ph.D

Researcher
Tallinn University of Technology

Anna is a third-year industrial PhD student at Tallinn University of Technology (TalTech). She is doing her research at the Center of Food and Fermentation Technologies (TFTAK).

The focus of her research is on next-generation probiotics and consortia manufacturing. She develops innovative ways how to manufacture stable consortia. That involves finding out how to control species ratios – support slower-growing species while avoiding the dominance of others. All that demands excellent knowledge of all the species. For that chemically defined media, isothermal microcalorimetry or bioreactors, metabolomics and consortia metabolic modelling is used. Anna has over five years of experience in the lab. Her previous studies involve acetoin microbial production and laboratory evolution.

 

Jonathan Weiss

PhD, MBA
VP of Corporate and Business Development

Dr. Weiss completed his PhD at the NYU School of Medicine where he studied immune tolerance through the interactions of Treg and Th17 cells. Upon graduation he began working at Kadmon Pharmaceuticals as a scientist developing the first ROCK2 inhibitor. The drug, Rezurock (Belumosudil), was granted Orphan Drug and Breakthrough Therapy Designations by the FDA and bypassed a Phase III clinical trial. The drug was approved by the FDA in August 2021 for Chronic Graft Versus Host Disease (cGVHD). After completing his MBA, Dr.

Jonathan Weiss

PhD, MBA
VP of Corporate and Business Development

Jonathan Weiss

PhD, MBA
VP of Corporate and Business Development

Dr. Weiss completed his PhD at the NYU School of Medicine where he studied immune tolerance through the interactions of Treg and Th17 cells. Upon graduation he began working at Kadmon Pharmaceuticals as a scientist developing the first ROCK2 inhibitor. The drug, Rezurock (Belumosudil), was granted Orphan Drug and Breakthrough Therapy Designations by the FDA and bypassed a Phase III clinical trial. The drug was approved by the FDA in August 2021 for Chronic Graft Versus Host Disease (cGVHD). After completing his MBA, Dr. Weiss joined the Stellate Therapeutics team to help move their therapeutics programs towards the clinic.

 

Joseph Maxwell

Associate Director of Translational Research and Biomarkers
Takeda

Dr. Maxwell trained as an immunologist at Oregon State University and the University of Connecticut Health Center. He spent 15 years supporting early target discovery and program leadership at Amgen, AbbVie, and Finch Therapeutics with an emphasis in inflammatory bowel disease. He is currently an Associate Director of Translational Research and Biomarkers at Takeda supporting clinical programs testing microbiome therapies and other novel modalities in IBD and celiac disease.

Joseph Maxwell

Associate Director of Translational Research and Biomarkers
Takeda

Joseph Maxwell

Associate Director of Translational Research and Biomarkers
Takeda

Dr. Maxwell trained as an immunologist at Oregon State University and the University of Connecticut Health Center. He spent 15 years supporting early target discovery and program leadership at Amgen, AbbVie, and Finch Therapeutics with an emphasis in inflammatory bowel disease. He is currently an Associate Director of Translational Research and Biomarkers at Takeda supporting clinical programs testing microbiome therapies and other novel modalities in IBD and celiac disease.

 

Laurent Chesnel

VP, Research & Development
Artugen Therapeutics

Laurent Chesnel

VP, Research & Development
Artugen Therapeutics

Laurent Chesnel

VP, Research & Development
Artugen Therapeutics
 

Magali Cordaillat

Scientific and Regulatory Affairs Director
Pharmabiotics Research Institute

Dr. Magali Cordaillat-Simmons earned her PhD in 2005 at the Université Paris V René Descartes, France, in Pharmacology, and her second Master’s degree in Pharmaceutical Regulatory Affairs at the Strasbourg Pharmacy School in 2014. Following her doctoral work with Pr.

Magali Cordaillat

Scientific and Regulatory Affairs Director
Pharmabiotics Research Institute

Magali Cordaillat

Scientific and Regulatory Affairs Director
Pharmabiotics Research Institute

Dr. Magali Cordaillat-Simmons earned her PhD in 2005 at the Université Paris V René Descartes, France, in Pharmacology, and her second Master’s degree in Pharmaceutical Regulatory Affairs at the Strasbourg Pharmacy School in 2014. Following her doctoral work with Pr. Ariel Gomez in pediatric nephrology at the University of Virginia from 2006 to 2009, Magali joined the newly-created Pharmabiotic Research Institute (PRI), which is an industrial-scientific Association dedicated to supporting the field in the development and registration of microbiome-based medicinal products for the European market. As Scientific and Regulatory Affairs Director, and in close collaboration with the PRI’s more than 80 industry members and academic partners, she oversees the organization’s EU-wide initiatives, which include EU-funded R&I projects, national and EU-level scientific advice request dossiers, and collaborative Task Group work on shared challenges for the field (CMC, standardization efforts, clinical design).

 

Paul Garofolo

CEO
Locus Biosciences

Paul Garofolo

CEO
Locus Biosciences

Paul Garofolo

CEO
Locus Biosciences
 

Tomas de Wouters

CEO
PharmaBiome

Tomas de Wouters

CEO
PharmaBiome

Tomas de Wouters

CEO
PharmaBiome
 

Dr Chris Callewaert

Post-doctoral researcher
Centre for Microbial Ecology & Technology, Ghent University

Chris received his PhD from Ghent University in Belgium. He is now a postdoctoral research fellow in the Knight lab at the University of California, San Diego. He investigates body odor and the characteristics of the bacteria living in the armpits, skin, clothes, washing machines and homes. He is the first to undertake bacterial transplants to solve underarm body odour.

Dr Chris Callewaert

Post-doctoral researcher
Centre for Microbial Ecology & Technology, Ghent University

Dr Chris Callewaert

Post-doctoral researcher
Centre for Microbial Ecology & Technology, Ghent University

Chris received his PhD from Ghent University in Belgium. He is now a postdoctoral research fellow in the Knight lab at the University of California, San Diego. He investigates body odor and the characteristics of the bacteria living in the armpits, skin, clothes, washing machines and homes. He is the first to undertake bacterial transplants to solve underarm body odour.

 

Christian Röhrig

Director of Operations
Micreos

Christian Röhrig

Director of Operations
Micreos

Christian Röhrig

Director of Operations
Micreos
 

Lada Rasochova

Founder & CEO
Dermala

Lada Rasochova

Founder & CEO
Dermala

Lada Rasochova

Founder & CEO
Dermala
 

Marie Drago

Founder
Gallinée

Marie Drago is a Doctor in Pharmacy and the founder of Gallinee. Launched in 2016 in London, the brand has been caring for the skin and its microbiome though innovative products across a number of categories.

Marie Drago

Founder
Gallinée

Marie Drago

Founder
Gallinée

Marie Drago is a Doctor in Pharmacy and the founder of Gallinee. Launched in 2016 in London, the brand has been caring for the skin and its microbiome though innovative products across a number of categories.

 

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics.

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnific® has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific® has successfully been launched in October 2019. 

 

Dr Yuri Martina

Chief Medical Officer
Destiny Pharma

Dr Yuri Martina

Chief Medical Officer
Destiny Pharma

Dr Yuri Martina

Chief Medical Officer
Destiny Pharma
 

Todd Krueger

President & CEO
AOBiome

Todd Krueger

President & CEO
AOBiome

Todd Krueger

President & CEO
AOBiome
 

Trevor Steyn

CEO & Founder
Esse Organic Skincare

Trevor Steyn is the CEO and founder of Esse Skincare. As an organic chemist his research has taken a broader approach to optimising skin health in the long term. Esse launched its first live probiotic product in February 2015 and has subsequently pioneered several new technologies in modulating the skin microbiome.  

 

Trevor Steyn

CEO & Founder
Esse Organic Skincare

Trevor Steyn

CEO & Founder
Esse Organic Skincare

Trevor Steyn is the CEO and founder of Esse Skincare. As an organic chemist his research has taken a broader approach to optimising skin health in the long term. Esse launched its first live probiotic product in February 2015 and has subsequently pioneered several new technologies in modulating the skin microbiome.  

 

 

Amine Zorgani Ph.D

Head of Research & Development
S-Biomedic

Amine Zorgani Ph.D

Head of Research & Development
S-Biomedic

Amine Zorgani Ph.D

Head of Research & Development
S-Biomedic
 

Chiara Heidi

Founder
Brightcure

Chiara Heidi

Founder
Brightcure

Chiara Heidi

Founder
Brightcure
 

Simone Guglielmetti

Assistant Professor
University of Milan

Simone Guglielmetti

Assistant Professor
University of Milan

Simone Guglielmetti

Assistant Professor
University of Milan
 

Eline Klaassens

Product Manager Human Health
Baseclear

Eline Klaassens

Product Manager Human Health
Baseclear

Eline Klaassens

Product Manager Human Health
Baseclear
 

Patrick Tripp

Laboratory Director
Zymo Research

Patrick Tripp

Laboratory Director
Zymo Research

Patrick Tripp

Laboratory Director
Zymo Research
 

Cécile Clavaud

Project Leader
Skin Microbiome Unit, L'oreal Research & Innovation

Cécile Clavaud

Project Leader
Skin Microbiome Unit, L'oreal Research & Innovation

Cécile Clavaud

Project Leader
Skin Microbiome Unit, L'oreal Research & Innovation
 

Isabelle de Cremoux

CEO
Seventure

Isabelle de Cremoux

CEO
Seventure

Isabelle de Cremoux

CEO
Seventure
 

Kristin Wannerberger

Director R&D Alliance Management
Ferring Pharmaceuticals

Kristin holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology. Kristin has more than 20 years of experience of Pharmaceutical Industry working with development of drugs covering various therapeutical areas and several administration forms. She has had various positions based in Sweden, Denmark and Switzerland and currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in the field of the human microbiota/microbiome.

Kristin Wannerberger

Director R&D Alliance Management
Ferring Pharmaceuticals

Kristin Wannerberger

Director R&D Alliance Management
Ferring Pharmaceuticals

Kristin holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology. Kristin has more than 20 years of experience of Pharmaceutical Industry working with development of drugs covering various therapeutical areas and several administration forms. She has had various positions based in Sweden, Denmark and Switzerland and currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in the field of the human microbiota/microbiome.

 

Audrey Gueniche Ph.D

HEAD OF INTERNATIONAL SCIENTIFIC VALORISATION LUXURY DIVISION
L'Oréal

Audrey GUENICHE obtained her Pharmacist degree and her PhD degree in skin biology more than 23 years ago. She is an expert on immunology and microbiology. Her main expertise is on skin topical treatment and food supplement for skin and hair health, especially using probiotics, natural extract and bacterial extracts. She is currently a senior clinical expert in LOREAL RESEARCH. She has a complete experience from the actives through vitro evaluations/ preclinical studies to clinical trials.

Audrey Gueniche Ph.D

HEAD OF INTERNATIONAL SCIENTIFIC VALORISATION LUXURY DIVISION
L'Oréal

Audrey Gueniche Ph.D

HEAD OF INTERNATIONAL SCIENTIFIC VALORISATION LUXURY DIVISION
L'Oréal

Audrey GUENICHE obtained her Pharmacist degree and her PhD degree in skin biology more than 23 years ago. She is an expert on immunology and microbiology. Her main expertise is on skin topical treatment and food supplement for skin and hair health, especially using probiotics, natural extract and bacterial extracts. She is currently a senior clinical expert in LOREAL RESEARCH. She has a complete experience from the actives through vitro evaluations/ preclinical studies to clinical trials. Her passion is to always reinvent evaluation and find new fields of area in term of actives to promote. 

She has published over 110 papers in peer-reviewed journals, 5 chapters in books, 2 specials issues in journal where she was the invited editor. She presented in over 80 international congresses and additionally she was personally invited to give more than 35 keynote lectures.

 

Leo Lathi

Associate Professor
University of Turku

Leo Lathi

Associate Professor
University of Turku

Leo Lathi

Associate Professor
University of Turku

FIND OUT MORE

The agenda for Microbiome Connect: Europe 2023 will be released very soon.

Fill out this form to register your interest and be the first to recieve the agenda when it becomes available!

REGISTER YOUR INTEREST

ABOUT THE EVENT

Microbiome Connect: Europe is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.

As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.

Furthermore, separate tracks will be committed to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skin care applications.

Join us to hear from microbiome biotechs, pharma voices, investment bodies, consumer product brands and more on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.

 

 

150+
Attendees
50+
Industry Leading Speakers
10+
Hours of Dedicated Networking

2022 AUDIENCE BREAKDOWN

35%
Biotech and BioPharma
15%
Academics
35%
Big Pharma
5%
Investors

Biotech and BioPharma

Academics

Big Pharma

Investors

Service Providers

Sequencers, CRO's, CDMO's, Ingredient companies, Consultants

Venue

Hotel Okura Amsterdam, Ferdinand Bolstraat 333, 1072 LH Amsterdam, Netherlands

Microbiome Connect invites you to join us at Hotel Okura on the 6 - 7th July 2022.

Click here to view local hotels.

Founders Forum

The Microbiome Connect: Founders Forum is a business network, strictly for biotechs which encourages peer-to-peer networking and collaboration.

During Microbiome Connect, we invite CEO’s, Founders and Business Leaders to collaborate, brainstorm ideas, share pain and find solutions to the current challenges surrounding research, development, manufacture, regulation and investment.

The Founders Forum will guide each attendee through a series of group discussion with other biotech leaders to get straight to the heart of the issues at the top of their priority list.

If you are interested in being a part of the Founders Forum, make sure to click the Founders forum opt-in box when registering for the event. 

REGISTER YOUR PLACE

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

OUR MICROBIOME COMMUNITY

Resources

Download Resource

TESTIMONIALS

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

REGISTER YOUR INTEREST

Fill in your details below to get in touch with our Sanctions & Export Controls Webinar team.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us